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Abstract
Background—Vaccination Program for US-bound Refugees (VPR) currently provides one or 
two doses of some age-specific Advisory Committee on Immunization Practices (ACIP)-
recommended vaccines to US-bound refugees prior to departure.
Methods—We quantified and compared the full vaccination costs for refugees using two 
scenarios: (1) the baseline of no VPR and (2) the current situation with VPR. Under the first 
scenario, refugees would be fully vaccinated after arrival in the United States. For the second 
scenario, refugees would receive one or two doses of selected vaccines before departure and 
complete the recommended vaccination schedule after arrival in the United States. We evaluated 
costs for the full vaccination schedule and for the subset of vaccines provided by VPR by four age-
stratified groups; all costs were reported in 2015 US dollars. We performed one-way and 
probabilistic sensitivity analyses and break-even analyses to evaluate the robustness of results.
Results—Vaccination costs with the VPR scenario were lower than costs of the scenario without 
the VPR for refugees in all examined age groups. Net cost savings per person associated with the 
VPR were ranged from $225.93 with estimated Refugee Medical Assistance (RMA) or Medicaid 
payments for domestic costs to $498.42 with estimated private sector payments. Limiting the 
analyses to only the vaccines included in VPR, the average costs per person were 56% less for the 
VPR scenario with RMA/Medicaid payments. Net cost savings with the VPR scenario were 
sensitive to inputs for vaccination costs, domestic vaccine coverage rates, and revaccination rates, 
but the VPR scenario was cost savings across a range of plausible parameter estimates.
Conclusions—VPR is a cost-saving program that would also reduce the risk of refugees arriving 
while infected with a vaccine preventable disease.
Corresponding Author: Heesoo Joo, PhD, Division of Global Migration and Quarantine, U.S. Centers for Disease Control and 
Prevention, 1600 Clifton Road, MS E-03, Atlanta, GA 30333, USA, Tel: +1 404 718 1667, Fax: +1 404 471 8864, hjoo@cdc.gov. 
Conflicts of interest: None
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention or the institutions with which the authors are affiliated.
HHS Public Access
Author manuscript
Vaccine. Author manuscript; available in PMC 2019 May 11.
Published in final edited form as:














US-bound refugees; overseas vaccination; cost analysis
1. Introduction
In fiscal year (FY) 2015, about 70,000 refugees resettle in the United States [1]. Unlike other 
immigrants, refugees are not required to have any vaccinations before US arrival. Lack of 
immunity among refugees may cause outbreaks of vaccine-preventable diseases (VPDs) in 
US communities and lead to significant public health-response costs [2]. To improve the 
health of US-bound refugees and reduce costs, the US Centers for Disease Control and 
Prevention (CDC) initiated the overseas Vaccination Program for US-bound Refugees 
(VPR) in December 2012 [3]. VPR is a collaboration between the US CDC’s Division of 
Global Migration and Quarantine and the US Department of State’s Bureau of Population, 
Refugees, and Migration. The program is implemented mainly by the International 
Organization for Migration (IOM). For 2012 through 2015, IOM administered vaccines in 
six countries—Ethiopia, Kenya, Malaysia, Nepal, Thailand, and Uganda. IOM and CDC are 
expanding VPR to 21 countries for FY 2017 [3]. In addition to administering the 
recommended vaccines, IOM transcribes valid vaccination records into official documents to 
share with health departments after refugees arrive.
After arrival in the United States, refugees are covered by either Medicaid or federally 
funded Refugee Medical Assistance (RMA) for at least 8 months [4]. During this period, 
vaccines for refugees would be primarily reimbursed through direct or indirect federal 
payments [4]. The US CDC recommends that refugees undergo a comprehensive medical 
exam within 90 days after arrival. Vaccines may be delivered at the comprehensive exam or 
follow-up appointments.
Relative to the baseline scenario, in which all vaccines are delivered after arrival in the 
United States, VPR is expected to decrease vaccination costs per fully vaccinated individual 
because vaccination costs are lower overseas compared to costs in the United States. We 
conducted a comparative cost analysis of fully vaccinating a US-bound refugee according to 
the Advisory Committee on Immunization Practices (ACIP) recommendations for age, with 
and without VPR, to estimate cost savings.
2. Data and Methods
We estimated the costs for refugees to complete the relevant age-appropriate, ACIP-
recommended vaccination schedule, according to two scenarios: 1) the pre-2012 baseline 
with no VPR, in which all refugee vaccinations would occur after US arrival (‘No VPR’ 
scenario) and 2) the current situation with VPR, and US follow-up to complete 
recommended vaccination schedules (‘VPR’ scenario). Under the ‘VPR’ scenario, refugees 
received one or two doses of selected vaccines prior to departure and additional vaccines to 
complete their age-appropriate schedule after resettlement in the United States. All costs 
were estimated in 2015 US dollars from the US payers perspective [5]. Costs were not 
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discounted because we assumed refugees would complete age-specific, recommended catch-
up schedules [6, 7] within a 1-year time horizon.
We included all age-specific, ACIP-recommended vaccines except influenza in the catch-up 
schedule in the analyses [6, 7]. To facilitate the analyses, US bound-refugees were divided 
into four age groups based on the age they were able to start immunization: 1) infant to 4.9 
years old, 2) 5–10.9 years old, 3) 11–18.9 years old, and 4) ≥19 years old. VPR provides one 
to two doses of the following vaccines: hepatitis B (HepB); diphtheria, tetanus, and pertussis 
(DTP); tetanus, diphtheria (Td); Haemophilus influenzae type b (Hib); Pentavalent (HepB-
Hib-DTP); oral poliovirus (OPV); and measles, mumps, and rubella (MMR).
Domestic vaccination costs for refugees
We used Medicaid reimbursement rates as the base case since RMA reimbursement rates are 
similar to Medicaid rates. Because Medicaid beneficiaries aged 0 through 18 years are 
eligible for the Vaccines for Children (VFC) program [8], base case and lower-bound costs 
of pediatric vaccines were estimated using the US CDC purchasing costs for the VFC from 
the 2015 Pediatric/VFC Vaccine Price List [9].
Base case costs of adult vaccines were estimated using 2014 MarketScan Medicaid multi-
state data, which was adjusted to 2015 prices by using the average change in private sector 
prices between 2014 and 2015 [9]. The lower-bound estimates were government purchasing 
rates for the Section 317 Immunization Program for uninsured or underinsured adults [10], 
and the upper-bound estimates were private sector prices from the 2015 Adult Vaccine Price 
List [9].
We used Current Procedural Terminology (CPT) codes 90460 and 90461 to estimate vaccine 
administration fees for refugees younger than 19 years old. For adults, CPT codes 90471 and 
90472 were used. Estimated vaccine administration fees for Medicaid beneficiaries in 2015 
were used for the base case and lower-bound estimates. The upper-bound cost estimate was 
the midpoint of private sector fee ranges from Healthcare Solutions’ 2015 Physicians’ Fee & 
Coding Guide [11].
Overseas vaccination costs for US-bound refugees
For vaccine costs, we used the weighted average cost per dose by vaccine, using FY 2017 
country-specific budgets weighted by the expected number of US-bound refugees from each 
country and the expected numbers of pediatric and adult vaccines purchased. For program 
administration costs, we assumed that there were fixed and variable costs. The fixed cost per 
refugee, which is independent of the numbers of doses given to each refugee, included the 
office, office overhead, and HepB surface antigen (HBsAg) test costs. The variable costs 
were estimated per dose delivered, and included staff, staff overhead, and non-vaccine 
operational costs. The lower-bounds are the first quartile of vaccine and program costs 
across the budgets of the VPR-implementing countries, while the upper-bounds are the third 
quartile of budgeted costs. We assumed that per dose and per person costs in FY 2017 
budget were equivalent to those costs in 2015.
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Estimation of per person costs by scenario
For the ‘No VPR’ scenario, the number of doses per refugee to achieve full vaccination by 
age was multiplied by the domestic vaccination cost per dose to estimate domestic 
vaccination costs per person by vaccine. Per-person vaccination costs by vaccine for each 
age group were summed to estimate costs of vaccination per refugee.
For the ‘VPR’ scenario, overseas and domestic vaccination costs were included. For each 
vaccine provided by VPR, we multiplied the number of doses given per person by the sum 
of the overseas vaccine and variable program costs per dose. We added estimates for all 
vaccines required by age group, and added the overseas fixed program cost per person to 
estimate the total overseas vaccination costs per person. The remaining numbers of doses 
after arrival were estimated by subtracting the numbers of doses provided by the VPR from 
the numbers of doses to fulfill the ACIP-recommended schedule by age for each vaccine. 
Then, we followed the same steps used to estimate domestic vaccination costs under the ‘No 
VPR’ scenario to estimate domestic vaccination costs under the ‘VPR’ scenario.
Because vaccines that are not currently included in VPR incurred the same costs under both 
scenarios, we separately examined the costs for VPR vaccines (i.e., DTaP/DTP/Tdap/Td, 
HepB, Hib, IPV/OPV, and MMR) to focus more directly on the relative costs of pre-
departure versus post-arrival vaccination costs for US-bound refugees.
Sensitivity analyses
We conducted sensitivity analyses to evaluate the robustness of our results. We performed 
one-way sensitivity analyses by setting one cost parameter at the lower- and upper-bound 
estimates while keeping all other parameters fixed at base case values. In addition, we 
conducted break-even analyses for domestic coverage rates and domestic revaccination rates. 
For the base case analysis, we assumed all refugees completed ACIP-recommended 
vaccination schedules after arrival in the United States. However, some refugees might not 
complete the vaccination schedule after arrival. Also, some refugees might be unnecessarily 
revaccinated after arrival because some healthcare providers might not consider overseas 
doses to be valid.
For break-even analysis, we varied the domestic coverage rates between 0% (no domestic 
vaccination) and 100% (complete domestic vaccination) and identified the coverage rate for 
which the costs for the ‘VPR’ and ‘No VPR’ scenarios were equivalent. We also estimated 
the numbers of doses of each vaccine received by refugees at the break-even domestic 
coverage rate. We varied the revaccination rate from 0% (no domestic revaccination) to 
100% (none of the doses provided overseas are considered valid in the United States) to 
investigate the effect of revaccination on vaccination costs.
To perform probabilistic sensitivity analyses (PSA), we used a Monte Carlo Simulation 
approach to randomly draw input parameters 10,000 times from independent probability 
distributions to estimate 99% credibility intervals [12]. More details about data and methods 
are provided in the Appendix.
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Vaccination costs under the ‘VPR’ scenario were lower than the costs under the ‘No VPR’ 
scenario across age groups (Table 1). The average full vaccination costs for the ‘No VPR’ 
scenario were $785.22 per person after weighting by age, while average costs under the 
‘VPR’ scenario were $559.30 per person. Thus, the ‘VPR’ scenario saved $225.93 per 
person compared to the ‘No VPR’ scenario. The implementation of VPR reduced full 
domestic vaccination costs by 29%. For the VPR vaccines, the costs per person were 56% 
less for the ‘No VPR’ scenario ($406.66) versus the ‘VPR’ scenario ($180.73) (Table 1). 
Among the net cost savings of $225.93 per person, 79% ($177.47 per person) is from 
reduced vaccine costs and the remaining 21% ($48.46 per person) is from reduced vaccine 
administration costs (Table 2).
The results of one-way sensitivity analyses of net cost savings associated with VPR are 
shown in Figure 1. Uncertainty in the domestic vaccine administration fee had the largest 
impact on net cost savings (range: $225.93–$414.51 per person). The ‘VPR’ scenario was 
less expensive than the ‘No VPR’ scenario across all one-way sensitivity analyses.
When the domestic coverage rates are varied between 100% (base case) and 0%, the net cost 
savings of the ‘VPR’ scenario compared to the ‘No VPR’ scenario varied from $225.93 per 
person to −$46.17 per person in Figure 2. At 0% domestic coverage (i.e. if refugees only 
receive VPR vaccines without additional vaccination after US arrival), the resulting net cost 
of $46.17 per refugee is equivalent to the average overseas vaccination costs per refugee. 
The break-even domestic coverage rate is 17%, for which costs of the ‘VPR’ and ‘No VPR’ 
scenarios are equivalent. At this break-even domestic coverage rate, refugees would receive 
an average of 6.9 doses under the ‘VPR’ scenario, compared to just 1.6 doses under the ‘No 
VPR’ scenario. For the domestic revaccination rates (Figure 3), the net cost savings per 
person varied from $225.93 with the base case of 0% domestic revaccination rates to −
$46.17 with the rate of 100%. The break-even revaccination rate was 83%.
From PSA, the 99% credibility interval (CI) of net cost savings of the ‘VPR’ scenario 
compared to the ‘No VPR’ scenario ranges from $221.4 to $301.4 (Table 1). The results of 
PSA also confirm the robustness of net savings with the VPR.
4. Discussion
The net cost savings due to the VPR are $225.93 (29%) per person, assuming that a refugee 
complete all ACIP-recommended vaccination schedules. When we limited the analysis to 
vaccines included in VPR, the ‘VPR’ scenario is 56% less costly than the ‘No VPR’ 
scenario. The results are consistent with a previous analysis of pre-departure vaccination for 
US-bound refugees, which estimated $235 net cost savings per-refugee in 2005 US dollars 
($285 per refugee in 2015 US dollars) for vaccines included in VPR [13].
The total amount of annual net cost savings associated with VPR depends on numbers of 
refugee arrivals per year, coverage rates of VPR, distribution of departed locations, and the 
net cost saving per person. Based on results from our analyses, the base case estimates of 
annual cost savings under the ‘VPR’ scenario compared to ‘No VPR’ scenario are $15.8 
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million, assuming an average of 70,000 refugee arrivals per year [1]. The estimated annual 
cost savings are ranged from $11.3 million assuming 50,000 arrivals to $24.9 million 
assuming 110,000 arrivals.
Since the number of refugees and distribution of countries from which refugees depart varies 
year-to-year, the potential cost savings from the VPR will vary. VPR comprised about 72% 
of total refugee arrivals in FY 2016. The extension of VPR to 100% coverage of US-bound 
refugees would increase annual net cost savings. However, depending on the distribution of 
US-bound refugees in any given year, it could also decrease average net cost savings per 
person because of higher operational, and logistics costs in some countries, which are not 
currently covered by VPR. The expansion of VPR to additional countries requires time to 
recruit and train staff, to ensure adequate power supplies for vaccine cold chains, and 
possibly to obtain permission to import certain vaccines in selected countries.
The base case estimates are based on a conservative assumption that RMA or Medicaid 
cover all vaccination costs for refugees. When we use the estimated private sector payments 
for domestic costs, the upper-bound annual cost savings are $34.9 million with 70,000 
refugee arrivals per year ($498.42 per-refugee, Appendix Table A16). The upper-bound 
estimate is a plausible estimate when state or federal funding may not cover the domestic 
vaccination costs of refugees.
VPR is also expected to reduce costs as compared to delivering all vaccines post-arrival, 
even if 1) the domestic vaccination coverage rate is low or 2) the domestic revaccination rate 
is high. The results from the break-even analyses showed that the ‘VPR’ scenario could 
reduce costs as long as the domestic vaccination coverage rate is greater than 17%. The 
domestic vaccination coverage rates lower than 17% are not realistic because of federal, 
state, and local vaccination requirements. Most refugees present for recommended post-
arrival medical examinations, which provide at least one opportunity for refugees to receive 
vaccines. Most children have to demonstrate that they have received the ACIP-recommended 
vaccines to satisfy state and local requirements for daycare and school entry, unless they are 
exempted because of medical, religious, or other reasons [4, 14]. Although adults may not 
have these requirements, at least one dose of each ACIP-recommended vaccine is required to 
adjust their immigration status to become a legal permanent resident [15]. Refugees can 
begin applying for a permanent residence 1 year after arriving in the United States [4].
Furthermore, even if cost savings are less than expected due to low domestic coverage rates, 
refugees would still receive more doses of vaccines under the ‘VPR’ scenario. For example, 
the average number of VPR vaccine doses per person is 9.3 doses to fulfill the ACIP-
recommended schedule for these VPR vaccines, while an average of 6.4 doses per person 
(67% completion) are given under the ‘VPR’ scenario prior to departure. At the break-even 
domestic coverage rate (17%), refugees would have received a total of 6.9 doses under the 
‘VPR’ scenario (6.4 overseas doses and 0.5 domestic doses), compared to just 1.6 doses 
under the ‘No VPR’ scenario.
For coverage rates greater than 17%, the ‘VPR’ scenario is both less expensive and achieves 
better health outcomes, because refugees would almost always receive more vaccine doses 
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under the ‘VPR’ scenario compared to the ‘No VPR’ scenario. The reduced risk of infection 
with VPDs under the ‘VPR’ scenario is especially important, since refugees are less likely to 
be protected from these diseases prior to departure than after arrival in the United States [2, 
4, 16, 17]. Thus, VPR should reduce the possibility that refugees could arrive in the United 
States with a VPD, initiating a VPD outbreak in their new US communities. These potential 
health benefits are not considered in our analyses, as discussed in the limitations below.
The second break-even analysis considers the potential for domestic revaccination to reduce 
the cost savings from the VPR. The revaccination rates higher than 83% would result in 
extra costs for the VPR. Another minor concern associated with revaccination is that over-
vaccination with some vaccines may increase the risk of adverse events. Revaccination 
might occur if domestic health departments do not use vaccination records from the VPR to 
determine how many doses of vaccines are required to fulfill the ACIP-recommended 
schedule after resettlement, either due to missing documentation or because healthcare 
workers decide that overseas doses are not valid. However, revaccination rates among 
refugees in the United States are expected to be much lower than the break-even 
revaccination rates identified in our analyses. For instance, the domestic MMR revaccination 
rates among newly arrived refugees were less than 11% during 2013–2015 [18].
Overall, VPR reduces the costs of refugee vaccination across a range of parameter 
assumptions and uncertainty analyses. Potential cost savings are divided across the federal 
VFC, federal RMA, and federal/state Medicaid programs. Although our evaluation includes 
the federal, states, and local governments’ payments, federal funding currently covers most 
vaccination costs for refugees. It is possible that the funds could be used for other public 
health programs to improve refugee health after resettlement.
Another strength of this evaluation is that we considered cost savings associated with adult 
vaccination among refugees. Adult vaccination in the United States does not get much 
attention compared to childhood vaccination [19]. However, adult vaccination is a serious 
concern for refugees who may not have been vaccinated as children. The estimates from this 
study showed substantial cost savings among adult refugees under the ‘VPR’ scenario, 
compared to the ‘No VPR’ scenario. Also, this evaluation used the actual program budget 
data to calculate overseas vaccination costs for refugees. The sensitivity analyses with 
overseas input parameters provide a reasonable range of estimates by using inputs from 
different countries. A retrospective evaluation of pre-departure vaccination costs for refugees 
using actual data has never been published elsewhere.
Other countries with refugee resettlement programs may also consider pre-departure 
vaccination programs. The pre-departure vaccination costs reported in this analysis could be 
used by those countries. Resettlement countries with similar domestic vaccination costs as 
the United States would also likely achieve net cost savings by vaccinating refugees before 
departure.
This evaluation has some limitations. First, we do not include potential cost savings resulting 
from any reductions in numbers of VPD cases and their sequelae. Prior to VPR, detection of 
measles and polio cases among US-bound refugees incurred costs to the federal government, 
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because refugee resettlement had to be postponed until outbreak control activities were 
implemented [2, 16]. The treatment and response costs of refugee-associated measles events 
in the United States were about $27,000 for a single case in 2010, and about $145,000 for an 
outbreak with seven cases in 2011 (2015 US dollars)[2, 4]. With VPR in place, it would not 
be necessary to postpone resettlement activities due to VPD cases, because US-bound 
refugees would be sufficiently protected due to vaccination. We expect that VPR could save 
additional outbreak response costs, and these additional savings would be significant.
Next, we assumed that domestic vaccine administration fees cover all costs for vaccination 
except vaccine costs. If the fees account for only some of staff and overhead costs for 
vaccination, net cost savings may be underestimated. Also, the overseas program costs 
included costs for HepB testing and documentation of valid overseas historical vaccinations. 
Our analyses, however, do not account for the potential health benefits of early diagnosis of 
HepB or for a reduction in domestic or overseas vaccination costs due to the documentation 
of historical (pre-VPR) vaccine doses. Thus, we may overestimate the overseas costs and 
underestimate the potential cost savings of VPR.
This analysis is not applicable to US asylees. Asylees, unlike refugees, seek legal status at 
US ports of entry or at land border crossings, and cannot be targeted for vaccination before 
arriving in the United States.
5. Conclusions
Our findings confirm that VPR significantly reduces vaccination costs for US-bound 
refugees, as compared to vaccination after arrival in the United States. Our estimates showed 
that net cost savings under VPR are about $225.93 per person with RMA or Medicaid 
payments for domestic costs. The expansion of VPR to include additional countries or 
additional vaccines would probably increase the US government’s cost savings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Vaccination Program for US-bound Refugees (VPR) provides selected 
vaccines overseas.
• VPR reduces vaccination costs for refugees across all age groups.
• Net savings per person vary from $226 (Medicaid rates for domestic costs) to 
$498 (private sector).
• Annual cost savings with VPR are $15.8–34.9 million (Medicaid-private 
sector) for 70K refugees.
• VPR reduces risks of refugees with potential for vaccine-preventable diseases 
outbreaks in the US.
Joo et al. Page 10














One-way sensitivity analyses for net cost savings per person by comparing costs under 
‘VPR’ scenario to costs under ‘No VPR’ scenario (2015 US dollars). The width of 
horizontal bars shows the change in net cost savings when each parameter was varied over 
the ranges as follows: A) domestic administration fee varies from the lower-bound of 
Medicaid reimbursement rates, which are as same as the baseline, to the upper-bound of 
private sector payments (Appendix Table A10); B) domestic vaccine cost varies from CDC 
vaccine purchasing price for non-insured or under-insured adults and Medicaid 
reimbursement rates for children (lower-bound, Appendix Tables A6–A7) to private sector 
payments (upper-bound, Appendix Tables A6–A7); and C) overseas program cost and 
vaccine cost vary from the lower-bound of the first quartile of country-specific costs from 
the VPR-implementing countries to the upper-bound of the third quartile of the country-
specific costs (Appendix Table A11).
Note: VPR, Vaccination Program for US-bound Refugees. When both domestic 
administration fee and vaccine costs vary from the lower-bound to the upper-bound, the net 
cost savings per person changed from $180.96 to $498.42. The upper-bound of net cost 
savings ($498.42) are based on private sector payments.
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Average net cost savings per person and average numbers of doses received per person for 
the ‘VPR’ and ‘No VPR’ scenarios by domestic coverage rates
Notes: DTaP, diphtheria, tetanus, and acellular pertussis; DTP, diphtheria, tetanus, and 
pertussis; Tdap, tetanus, diphtheria, and acellular pertussis; Td, tetanus, diphtheria; HepB, 
hepatitis B; Hib, Haemophilus influenzae type b; IPV, inactivated poliovirus; OPV, oral 
polio virus; MMR, measles, mumps, and rubella; VPR, Vaccination Program for US-bound 
Refugees. The analyses only included five vaccines, DTaP/DTP/Tdap/Td, HepB, Hib, IPV/
OPV, and MMR, which are provided through VPR. Baseline is 100% of the domestic 
coverage rate. The domestic coverage rate does not affect net cost savings for vaccines not 
included in VPR (e.g., varicella). The break-even points, indicated with the vertical dashed-
line, represent the domestic vaccine coverage rate for which the costs to US governments for 
the ‘VPR and ‘No VPR’ scenarios are equivalent. At the break-even coverage rate of 17.0%, 
refugee vaccination costs for the five VPR vaccines are $69 per person under both the ‘VPR’ 
and ‘No VPR’ scenarios. However, the refugees would receive an average of 6.9 doses under 
the ‘VPR’ scenario compared to just 1.6 doses under the ‘No VPR’ scenario.
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Average net cost savings per person (‘VPR’ vs. ‘No VPR’) by domestic revaccination rates
Notes: DTaP, diphtheria, tetanus, and acellular pertussis; DTP, diphtheria, tetanus, and 
pertussis; Tdap, tetanus, diphtheria, and acellular pertussis; Td, tetanus, diphtheria; HepB, 
hepatitis B; Hib, Haemophilus influenzae type b; IPV, inactivated poliovirus; OPV, oral 
polio virus; MMR, measles, mumps, and rubella; VPR, Vaccination Program for US-bound 
Refugees. The analyses only included five vaccines, DTaP/DTP/Tdap/Td, HepB, Hib, IPV/
OPV, and MMR, which are provided through VPR. Baseline is the 0% revaccination. The 
domestic coverage rate does not affect net cost savings for vaccines not included in VPR 
(e.g., varicella). The break-even revaccination rate, indicated with the vertical dashed-line, 
represents the rate the cost of the ‘VPR’ scenario is equal to the ‘No VPR’ scenario. At the 
break-even revaccination rate of 83%, the cost estimates for both the ‘VPR’ and ‘No VPR’ 
scenarios are $407 per person.
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